Judith Hibbard
Judith Hibbard has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Meredith O. Cruz
Division of Maternal Fetal Medicine, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226-3522, USA
2 shared publications Pippa Simpson
Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
2 shared publicationsAnna McCormick
Rush University Medical Center, Chicago, IL
1 shared publication- David M. Mosen
Kaiser Permanente Center for Health Research, United State
1 shared publication Deepa Ranganathan
University of Chicago
1 shared publicationElizabeth Neuman
Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
1 shared publication
Latest Publications
- Open Access
- 1 February 2021
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 224 (2) , S474-S475
758 Hypertensive disease of pregnancy (HDP) among high risk women with stage 1 hypertension
- 1 February 2021
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 224 (2) , S474-S475
Open Access758 Hypertensive disease of pregnancy (HDP) among high risk women with stage 1 hypertension
- 1 May 2017
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 129 (1) , S138-S139
Correlation of BMI to Magnesium Levels in Patients With Preeclampsia [24M]
To determine the relationship between BMI and magnesium blood levels following a 4 or 6 gram bolus of IV magnesium in preeclamptic women. Retrospective chart review from 2005 to 2015 analyzing magnesium levels in preeclamptic women. Patients received IV magnesium bolus (4 or 6 grams) followed by a basal rate of 2 grams/hour. Magnesium levels were then drawn approximately 4 hours after the bolus dose. Magnesium levels from 4.8 to 8.4 mg/dL were considered therapeutic. BMI and labs (creatinine, ALT, AST, platelets) were compared between therapeutic and sub-therapeutic groups. 508 patient charts reviewed; 207 met inclusion criteria. Patients with BMI less than or equal to 30 had fewer sub-therapeutic levels than therapeutic levels (Sub-therapeutic: 38.5%; Therapeutic: 61.5%; P-value less than 0.001). Patients with a BMI less than 30 had more sub-therapeutic levels than therapeutic (Sub-therapeutic: 76%; Therapeutic: 24%; P-value less than 0.001). In patients with BMI greater than 35, there were more patients in the sub-therapeutic group (Sub-therapeutic: 83%; Therapeutic: 17%; P-value 0.024). Creatinine was lower in the sub-therapeutic group compared to therapeutic group (Subtherapeutic: 0.66; Therapeutic: 0.73; P-value: 0.003). ROC curve demonstrated 4 gram magnesium bolus with BMI greater than or equal to 30 likely will not reach a therapeutic level (Sensitivity: 0.84, Specificity: 0.51), nor will 6 gram magnesium bolus with BMI greater than or equal to 35 (Sensitivity: 0.74, Specificity: 0.38). There is an inverse relationship between BMI and blood magnesium levels. When BMI reaches above 30, patients are more likely to be sub-therapeutic than therapeutic.
- 1 May 2017
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 129 (1) , S138-S139
Correlation of BMI to Magnesium Levels in Patients With Preeclampsia [24M]
To determine the relationship between BMI and magnesium blood levels following a 4 or 6 gram bolus of IV magnesium in preeclamptic women. Retrospective chart review from 2005 to 2015 analyzing magnesium levels in preeclamptic women. Patients received IV magnesium bolus (4 or 6 grams) followed by a basal rate of 2 grams/hour. Magnesium levels were then drawn approximately 4 hours after the bolus dose. Magnesium levels from 4.8 to 8.4 mg/dL were considered therapeutic. BMI and labs (creatinine, ALT, AST, platelets) were compared between therapeutic and sub-therapeutic groups. 508 patient charts reviewed; 207 met inclusion criteria. Patients with BMI less than or equal to 30 had fewer sub-therapeutic levels than therapeutic levels (Sub-therapeutic: 38.5%; Therapeutic: 61.5%; P-value less than 0.001). Patients with a BMI less than 30 had more sub-therapeutic levels than therapeutic (Sub-therapeutic: 76%; Therapeutic: 24%; P-value less than 0.001). In patients with BMI greater than 35, there were more patients in the sub-therapeutic group (Sub-therapeutic: 83%; Therapeutic: 17%; P-value 0.024). Creatinine was lower in the sub-therapeutic group compared to therapeutic group (Subtherapeutic: 0.66; Therapeutic: 0.73; P-value: 0.003). ROC curve demonstrated 4 gram magnesium bolus with BMI greater than or equal to 30 likely will not reach a therapeutic level (Sensitivity: 0.84, Specificity: 0.51), nor will 6 gram magnesium bolus with BMI greater than or equal to 35 (Sensitivity: 0.74, Specificity: 0.38). There is an inverse relationship between BMI and blood magnesium levels. When BMI reaches above 30, patients are more likely to be sub-therapeutic than therapeutic.
- 1 May 2017
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 129 (1) , 34S
Safety and Efficacy of the Foley Balloon for Cervical Ripening During Induction of Labor in Women With Prior Cesarean [15C]
Induction of labor in women with prior cesarean is a safe alternative to repeat cesarean. Current evidence has not determined the best method for women who require cervical ripening. We sought to determine whether the use of the Foley balloon is comparable in safety and efficacy to oxytocin. We conducted a retrospective chart review of all women with prior cesarean undergoing induction between 1990 and 2015. We compared the vaginal delivery rate, maternal adverse event composite, and neonatal adverse event composite. The maternal composite included hemorrhage, infection, uterine rupture, and maternal death. The neonatal composite included 5m Apgar < 7, umbilical artery pH < 7, NICU admission, and neonatal death. Confounding variables, including Bishop score, previous vaginal delivery, gestational age, and presence of PROM, were identified by logistic regression. 66 women were induced by Foley balloon and 405 by oxytocin. The vaginal delivery rate was significantly less in the Foley balloon group compared to the oxytocin group (55% vs 75%, p=0.001). The rates of maternal and neonatal adverse events were equivalent (24% vs 15%, p=0.070; 11% vs 10%, p=0.86). Logistic regression determined that women with 3 or more deliveries (odds ratio 0.22 (CI 0.01, 0.05)) and gestational age greater than 36 weeks (OR 0.30 (CI 0.11, 0.80)) were associated with decreased likelihood of maternal adverse events; premature rupture of membranes (OR 3.91 (CI 1.93, 7.92)) was associated with increased likelihood of neonatal adverse events. With careful patient selection, Foley balloon is an acceptable induction method in women with prior cesarean.
- 1 May 2017
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 129 (1) , 34S
Safety and Efficacy of the Foley Balloon for Cervical Ripening During Induction of Labor in Women With Prior Cesarean [15C]
Induction of labor in women with prior cesarean is a safe alternative to repeat cesarean. Current evidence has not determined the best method for women who require cervical ripening. We sought to determine whether the use of the Foley balloon is comparable in safety and efficacy to oxytocin. We conducted a retrospective chart review of all women with prior cesarean undergoing induction between 1990 and 2015. We compared the vaginal delivery rate, maternal adverse event composite, and neonatal adverse event composite. The maternal composite included hemorrhage, infection, uterine rupture, and maternal death. The neonatal composite included 5m Apgar < 7, umbilical artery pH < 7, NICU admission, and neonatal death. Confounding variables, including Bishop score, previous vaginal delivery, gestational age, and presence of PROM, were identified by logistic regression. 66 women were induced by Foley balloon and 405 by oxytocin. The vaginal delivery rate was significantly less in the Foley balloon group compared to the oxytocin group (55% vs 75%, p=0.001). The rates of maternal and neonatal adverse events were equivalent (24% vs 15%, p=0.070; 11% vs 10%, p=0.86). Logistic regression determined that women with 3 or more deliveries (odds ratio 0.22 (CI 0.01, 0.05)) and gestational age greater than 36 weeks (OR 0.30 (CI 0.11, 0.80)) were associated with decreased likelihood of maternal adverse events; premature rupture of membranes (OR 3.91 (CI 1.93, 7.92)) was associated with increased likelihood of neonatal adverse events. With careful patient selection, Foley balloon is an acceptable induction method in women with prior cesarean.
- Open Access
- 1 September 2014
- Published by Marshfield Clinic Research Institute in Clinical Medicine & Research
- Vol. 12 (1-2) , 106-107
PS1-23: Prospective Association of Patient Activation Measure (PAM) with Medical Costs among Hypertension Population
The patient activation measure (PAM) refers to an individual’s skills, knowledge, and confidence to manage their health and their ability to engage health providers in shared decision making practices. Such skills are important for the ongoing management of chronic conditions, such as hypertension. Although research has examined the association of PAM with utilization and health outcomes; little research has examined the association of PAM with medical costs. The objective of this research was to examine the prospective association of PAM with four cost measures: 1) total costs, 2) emergency department (ED) costs, 3) inpatient costs and 4) pharmacy costs. Using an observational study design, we studied 1,812 patients with hypertension with a PAM assessment between 12/4/2007 and 2/28/201. The PAM is 13 items and categorizes PAM into four levels: PAM 1(lowest level of activation, where patients typically lack confidence and self-management skills and may not understand the need to be actively involved in managing their health) and PAM 4 (highest activation where patients typically have the necessary self-management skills and are more pro-active about their health). Patients received care in Kaiser Permanente Northwest (KPNW) and were enrolled in care management programs. Per patient per month (PPPM) medical costs were calculated 12 months after the PAM assessment date. Costs were constructed in 4 areas: total, ED, inpatient and pharmacy. Using Ordinary Least Squares Regression, each cost measure was regressed on PAM level (PAM 1 [reference group] vs. PAM 2, PAM 3, and PAM 4); adjusting for the following covariate measures; demographics and a severity of illness. We performed statistical analyses on logged PPPM medical costs, but report comparisons in absolute dollars (2011). Compared to those with PAM 1 scores, those with PAM 3 scores had lower total costs (beta coefficient = − $849; P = .0004), ED costs (beta coefficient = − $22; P = .02) and inpatient costs (beta coefficient = − $500; P = .03). Among a population with hypertension; adults with higher PAM scores (PAM 3) had significantly lower total costs, ED costs and inpatient costs, compared to patients with lower PAM scores (PAM 1).
- 1 September 2014
- Published by Marshfield Clinic Research Institute in Clinical Medicine & Research
- Vol. 12 (1-2) , 106-107
Open AccessPS1-23: Prospective Association of Patient Activation Measure (PAM) with Medical Costs among Hypertension Population
The patient activation measure (PAM) refers to an individual’s skills, knowledge, and confidence to manage their health and their ability to engage health providers in shared decision making practices. Such skills are important for the ongoing management of chronic conditions, such as hypertension. Although research has examined the association of PAM with utilization and health outcomes; little research has examined the association of PAM with medical costs. The objective of this research was to examine the prospective association of PAM with four cost measures: 1) total costs, 2) emergency department (ED) costs, 3) inpatient costs and 4) pharmacy costs. Using an observational study design, we studied 1,812 patients with hypertension with a PAM assessment between 12/4/2007 and 2/28/201. The PAM is 13 items and categorizes PAM into four levels: PAM 1(lowest level of activation, where patients typically lack confidence and self-management skills and may not understand the need to be actively involved in managing their health) and PAM 4 (highest activation where patients typically have the necessary self-management skills and are more pro-active about their health). Patients received care in Kaiser Permanente Northwest (KPNW) and were enrolled in care management programs. Per patient per month (PPPM) medical costs were calculated 12 months after the PAM assessment date. Costs were constructed in 4 areas: total, ED, inpatient and pharmacy. Using Ordinary Least Squares Regression, each cost measure was regressed on PAM level (PAM 1 [reference group] vs. PAM 2, PAM 3, and PAM 4); adjusting for the following covariate measures; demographics and a severity of illness. We performed statistical analyses on logged PPPM medical costs, but report comparisons in absolute dollars (2011). Compared to those with PAM 1 scores, those with PAM 3 scores had lower total costs (beta coefficient = − $849; P = .0004), ED costs (beta coefficient = − $22; P = .02) and inpatient costs (beta coefficient = − $500; P = .03). Among a population with hypertension; adults with higher PAM scores (PAM 3) had significantly lower total costs, ED costs and inpatient costs, compared to patients with lower PAM scores (PAM 1).
- Open Access
- 16 July 2012
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 30 (01) , 053-058
Ambulatory Arrhythmia Monitoring in Pregnant Patients with Palpitations
Objective To assess the frequency of rhythm disturbances (RDs) obtained following placement of a Holter monitor or an event loop recorder (ERT) in patients referred to cardiologists. Study Design Ninety-six gravidas were referred to the cardiology clinic for palpitations, syncope, or dizziness and had Holter monitoring or ERT after a baseline electroencephalogram. Arrhythmias were classified by severity. Results Gestational age at referral was 22.6 weeks ± 8.3 days. Sixty-five patients had ERTs performed, and 19 had Holter monitors. Seventy-six percent had benign arrhythmias. In our ERT cohort, history of arrhythmias showed a fourfold increase in serious RD during gestation (odds ratio [OR] 4.7, 95% confidence interval [CI] 1.1 to 20.3, p = 0.01); obesity (body mass index >30) had a fourfold increased risk (OR 4.0, 95% CI 1.0 to 1, p = 0.03). Serious RD did not result in greater chance of cesarean delivery or induction of labor, or a newborn with arrhythmias. Conclusion Most pregnant women with palpitations have benign arrhythmias. ERT appears to be a better method of diagnosis in pregnant women.
- 16 July 2012
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 30 (01) , 053-058
Open AccessAmbulatory Arrhythmia Monitoring in Pregnant Patients with Palpitations
Objective To assess the frequency of rhythm disturbances (RDs) obtained following placement of a Holter monitor or an event loop recorder (ERT) in patients referred to cardiologists. Study Design Ninety-six gravidas were referred to the cardiology clinic for palpitations, syncope, or dizziness and had Holter monitoring or ERT after a baseline electroencephalogram. Arrhythmias were classified by severity. Results Gestational age at referral was 22.6 weeks ± 8.3 days. Sixty-five patients had ERTs performed, and 19 had Holter monitors. Seventy-six percent had benign arrhythmias. In our ERT cohort, history of arrhythmias showed a fourfold increase in serious RD during gestation (odds ratio [OR] 4.7, 95% confidence interval [CI] 1.1 to 20.3, p = 0.01); obesity (body mass index >30) had a fourfold increased risk (OR 4.0, 95% CI 1.0 to 1, p = 0.03). Serious RD did not result in greater chance of cesarean delivery or induction of labor, or a newborn with arrhythmias. Conclusion Most pregnant women with palpitations have benign arrhythmias. ERT appears to be a better method of diagnosis in pregnant women.
- 8 May 2009
- Published by Elsevier
- p. 249-267
Cardiovascular Alterations in Normal and Preeclamptic Pregnancy
- 8 May 2009
- Published by Elsevier
- p. 249-267
Cardiovascular Alterations in Normal and Preeclamptic Pregnancy
- 1 January 1997
- Published by Springer Nature
- p. 263-265
Obstetric Management and Group B Streptococcal Sepsis
- 1 January 1997
- Published by Springer Nature
- p. 263-265
Obstetric Management and Group B Streptococcal Sepsis
- 1 January 1995
- Published by Taylor & Francis in International Journal of the Addictions
- Vol. 30 (7) , 881-888
A Treatment Model for Women Substance Users
This paper sets forth a multifaceted program which consists of drug user women-centered counseling plus ancillary services based on the five basic steps of Freire's empowerment theory. The program is designed to increase self-awareness, skills, and knowledge acquisition, to reduce feelings of isolation by broadening interpersonal networks, includes activities to enhance assertiveness and communication skills, and parenting education to counteract inappropriate mother-child interaction as well as to positively influence role modeling. Both transportation and child care are recommended ancillary services.
- 1 January 1995
- Published by Taylor & Francis in International Journal of the Addictions
- Vol. 30 (7) , 881-888
A Treatment Model for Women Substance Users
This paper sets forth a multifaceted program which consists of drug user women-centered counseling plus ancillary services based on the five basic steps of Freire's empowerment theory. The program is designed to increase self-awareness, skills, and knowledge acquisition, to reduce feelings of isolation by broadening interpersonal networks, includes activities to enhance assertiveness and communication skills, and parenting education to counteract inappropriate mother-child interaction as well as to positively influence role modeling. Both transportation and child care are recommended ancillary services.